Cancer

Cidara Therapeutics Receives $11.14 Million Milestone Payment Following European Approval of REZZAYO

Approval triggered by positive results from ReSTORE Phase III clinical trialPayment will advance Cidara’s Cloudbreak platform for the development of…

10 months ago

BioXcel Therapeutics Receives FDA Fast Track Designation for BXCL701 for Treatment of Small Cell Neuroendocrine Prostate Cancer (SCNC)

Designation for BXCL701 in combination with a checkpoint inhibitor (CPI) for treatment of patients with metastatic SCNC with progression on…

10 months ago

Poolbeg Pharma PLC Announces Market Opportunity for POLB 001 for CRS

Independent Research Confirms >$10bn Market Opportunity for POLB 001 as a Preventative Therapy for Cancer Immunotherapy-Induced Cytokine Release Syndrome (CRS)Former…

10 months ago

Autonomix Medical, Inc. (NASDAQ:AMIX) to Present at Integrous Big Hearts, Big Ideas Virtual Investor Conference

Webcast presentation on Wednesday, February 14th at 10:30 AM ESTTHE WOODLANDS, TX / ACCESSWIRE / February 9, 2024 / Autonomix…

10 months ago

Correction: Nuvectis Pharma Announces Participation at Upcoming Investor Conferences

Fort Lee, NJ, Feb. 09, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage…

10 months ago

OneMedNet Sees Real World Data Growth in Women’s Health

MINNEAPOLIS, Feb. 09, 2024 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet” or the “Company”), the leading curator of regulatory-grade…

10 months ago

McKesson’s Practice Insights Designated as a 2024 Qualified Clinical Data Registry by Centers for Medicare & Medicaid Services

IRVING, Texas--(BUSINESS WIRE)--For the eighth consecutive year, McKesson has received approval from the Centers for Medicare & Medicaid Services (CMS)…

10 months ago

McKesson’s Practice Insights Designated as a 2024 Qualified Clinical Data Registry by Centers for Medicare & Medicaid Services

IRVING, Texas--(BUSINESS WIRE)--For the eighth consecutive year, McKesson has received approval from the Centers for Medicare & Medicaid Services (CMS)…

10 months ago

Dr. Michael Jewett Joins Theralase(R) to Help Complete Enrollment in the Phase II Non-Muscle Invasive Bladder Cancer Clinical Study

TORONTO, ON / ACCESSWIRE / February 8, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage…

10 months ago